More News

16 Nov 2018 MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210
15 Nov 2018 Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
15 Nov 2018 Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
15 Nov 2018 Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
14 Nov 2018 Dragonfly Therapeutics Announces Expansion of its Strategic Collaboration with Celgene, Doubling the Number of Programs and Including Targets for Solid Tumor Indications
13 Nov 2018 DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
13 Nov 2018 MaxCyte Announces Research Agreement with Kite, a Gilead Company
13 Nov 2018 Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor
13 Nov 2018 Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth
11 Nov 2018 BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
09 Nov 2018 CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
08 Nov 2018 Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics
08 Nov 2018 Saniona signs option agreement with Initiator Pharma
07 Nov 2018 Regulus Announces Successful Restructuring of Sanofi Collaboration
06 Nov 2018 Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease
06 Nov 2018 Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
05 Nov 2018 Grünenthal Acquires Global Rights for Qutenza
05 Nov 2018 Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
05 Nov 2018 MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
05 Nov 2018 Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
02 Nov 2018 BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease
02 Nov 2018 Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
01 Nov 2018 Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
01 Nov 2018 MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
31 Oct 2018 Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top